Book Chapters
Horacio Plotkin and Andrew Stewart. “Malignancy-associated hypercalcemia”. In: Clinical Endocrinology, McGraw Hill, UK. A Pinchera and JA Fischer (eds.) :231-237, 2001
Horacio Plotkin. “Prevención primaria de la osteoporosis” [Primary prevention of osteoporosis], In Osteoporosis. Fisiopatología, diagnóstico, prevención y tratamiento, Editorial Medica Panamericana, Buenos Aires, Argentina. JR. Zanchetta and JR. Talbot, (eds.) :410-412, 2001.
Horacio Plotkin, Dragan Primorac and David Rowe. “Osteogenesis imperfecta” In: Pediatric Bone – Biology and Diseases. FH Glorieux, H Juppner y JM Pettifor (eds.) :443-471, 2003
Horacio Plotkin and Richard Lutz. “Osteoporosis in pediatrics” In: Current topics in osteoporosis. Hong Wen Deng, (ed.) :362-414, 2005
Horacio Plotkin “Syndromes with brittle bones, Hyperostotic bone diseases and Fibrous dysplasia of bone” Pediatric Endocrinology, 5th Ed. Fima Lifshitz, (ed.) :559-580, 2007
Horacio Plotkin and Fima Lifshitz “Rickets and osteoporosis in pediatrics” Pediatric Endocrinology, 5th Ed. Fima Lifshitz, (ed.) :531-558, 2007
Peer-reviewed
1) Zanchetta J.R., Plotkin H., Alvarez Filgueira M.L. “Bone Mass In Children: Normative Values For The 2-20 Year-old Population”. Bone, 16, 4 :393s-399s, 1995
2) Plotkin H, Nuñez M, Alvarez Filgueira ML, Zanchetta JR. [“Factores determinantes de la densidad mineral ósea en una población argentina de 2 a 20 años de edad”] (Determinant factors of bone mineral density in argentine children 2-20 years of age) Archivos Argentinos de Pediatría, 94, 1 :14-20, 1996.
3) Plotkin H, Nuñez M, Alvarez Filgueira ML, Zanchetta JR. “Lumbar spine bone density in argentine children”, Calcified Tissue International, 58 :144-149, 1996
4) Zanchetta JR, Plotkin H, Roldan EJA. “Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance”. Calcified Tissue Int, 59:70-72, 1996
5) Zanchetta JR, Spivacow R, Bogado C, Sarli M, Plotkin H, Roldan E ["Uso prolongado, hasta 6 años, de un amino-bisfosfonato oral en pacientes con osteoporosis establecida”] (Long term usage, up to six years, of a oral bisphosphonate in patients with osteoporosis). Medicina (Buenos Aires) vol 57 supl.I :37-44, 1997
6) Plotkin, L.I., Sarli, M. , Sgarlata, C., Zanchetta, R.J., Plotkin, H., Leoni, J.,Mathov, I. [“Niveles Séricos de la Proteína Transportadora del Factor de Crecimiento Insulino-Símil-3 (Igfbp-3) y del Factor de Crecimiento Insulino-Símil-I (Igf-I) en Pacientes Osteoporóticas”] (Serum levels of Igfbp-3 and Igf-1 in osteoporotic patients). Revista Argentina de Endocrinologia y Metabolismo, 35 :67-75, 1998
7) JL Ferretti, RF Capozza, GR Cointry, SL Garcia, Plotkin H, ML Alvarez Filgueira, JR Zanchetta. Gender-related differences in the relationship between densitometric values of whole-body bone mineral content and lean body mass in humans between 2 and 87 years of age. Bone, 22:683-690, 1998.
8) FH Glorieux , NJ Bishop, Plotkin H, G Chabot, G Lanoue, R Travers. Cyclical pamidronate infusion in children with severe osteogenesis imperfecta. New England Journal of Medicine, 339:947-952, 1998
9) Plotkin H, C Gundberg, M Mitnick, AF Stewart. Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1-36) in humans: potential as an anabolic therapy for osteoporosis. Journal of Clinical Endocrinology and Metabolism, 83 :2786 - 2791, 1998
10) Juppner H; Schipani E; Bastepe M; Cole DE; Lawson ML; Mannstadt M; Hendy GN; Plotkin H; Koshiyama H; Koh T; Crawford JD; Olsen BR; Vikkula M.The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3 Proc Natl Acad Sci U S A Sep 29;95(20):11798-803, 1998
11) F H. Glorieux, F Rauch, Plotkin H, L Ward, R Travers, P Roughley, L Lalic, D F. Glorieux, F Fassier, N J Bishop. Type V Osteogenesis Imperfecta - a New Form of Brittle Bone Disease. Journal of Bone and Mineral Research, 15:1650-1658, 2000
12) Plotkin H, Rauch F, Bishop N, Montpetit K, Ruck-Gibis J, Travers R, Glorieux F. Pamidronate Treatment Of Severe Osteogenesis Imperfecta In Children Under Three Years Of Age. Journal of Clinical Endocrinology and Metabolism, 85:1846-1850, 2000
13) Ruck-Gibis J, Plotkin H, Hanley J, Wood-Duphinee S. Reliability of the Gross Motor Function Measure for children with osteogenesis imperfecta. Pediatric Physical Therapy,13:10-17, 2001.
14) EJA Roldán, O Quattrocchi, J Zanchetta, Plotkin H, G Araujo, E Piccinni Comparable Bioavailability Of Two Esophago-Gastric Protective Formulations Containing Pamidronate (APD). A Cross-Over Trial In Healthy Young Adults. Medicina (Buenos Aires), 62: 317-322, 2002
15) L Terpstra, F Rauch, Plotkin H, R Travers, FH Glorieux. Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis, Journal of Bone and Mineral Research, 17 (11):1949-1953, 2002.
16) F Rauch, R Travers, Plotkin H, FH Glorieux. The effects of intravenous pamidronate on the developing skeleton: a histomorphometric study in children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation, 110 (9):1293-1299, 2002
17) F Rauch, Plotkin H, R Travers, L Zeitlin, FH Glorieux. Osteogenesis Imperfecta Types I, III and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism. Journal of Clinical Endocrinology and Metabolism, 88(3):986-92, 2003
18) F Rauch, Plotkin H, L Zeitlin, FH Glorieux. Bone Mass, Size and Density in Children and Adolescents with Osteogenesis Imperfecta: Effect of Intravenous Pamidronate Therapy. Journal of Bone and Mineral Research, 18 (4):610-614, 2003.
19) L Zeitlin, F Rauch, Plotkin H, FH Glorieux. Height and Weight Development During Long-Term Therapy with Cyclical Intravenous Pamidronate in Children and Adolescents with Osteogenesis imperfecta Types I, III and IV. Pediatrics. 111: 1030-1036, 2003
20) K Montpetit, Plotkin H, F Rauch, N Bilodeau, S Cloutier, M Rabzel, FH Glorieux. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics, 111: e601-e603, 2003
21) Plotkin H, F Rauch, L Zeitlin, C Munns, R Travers, F H Glorieux. Effect of Pamidronate Treatment in Children with Polyostotic Fibrous Dysplasia of Bone. Journal of Clinical Endocrinology and Metabolism, 88:4569–4575 2003
22) Plotkin H Syndromes with congenital brittle bones, BioMed Central Pediatrics, 4:16, 2004
23) Pizones Arce J, Plotkin H, Parra-Garcia JI, Alvarez Gonzalez P, Gutierrez Diez P, Bueno Sanchez A, Fernandez Fernandez-Arroyo A. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. Journal of Pediatric Orthopedics, 25(3):332-335, 2005
24) Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G. “Low doses of pamidronate for the treatment of osteopenia in children with severe cerebral palsy: a pilot study” Developmental Medicine and Child Neurology, 48(9):709-12, 2006
Review articles
1) Sarli M, Plotkin H, Zanchetta J. [“Osteopatía alcohólica”] (Alcoholic Osteopathy), Medicina (Buenos Aires), 54 :363-370, 1994.
2) Plotkin H, Zanchetta JR [“Densitometría en niños y adolescentes”] (Densitometry in Children and Adolescents), Archivos Argentinos de Pediatría, 92 :181-184, 1994
3) Baylink D, Plotkin H, Zanchetta JR, Talbot J, [“Factores de crecimiento óseo”] (Bone Growth Factors). Revista Española de Enfermedades Metabólicas Oseas, 3 :189-190 (editorial comment), 1994.
4) Sarli M, Plotkin H, Zanchetta JR. [“Osteoporosis en hombres”] (Osteoporosis in men). Revista Argentina de Endocrinología y Metabolismo, 32 :208-213, 1996.
5) Plotkin H, L Plotkin, R Plotkin. [“Acciones fisiológicas de la proteína relacionada con la PTH (PTHrP)”] (Physiological actions of PTHrP) Revista Argentina de Endocrinologia y Metabolismo. 35 :169-178, 1998.
6) Plotkin H, L Plotkin, R Plotkin. [Uso De Bisfosfonatos En El Tratamiento De Pacientes Con Formas Juveniles De Osteoporosis] (Use of bisphosphonates for treatment of patients with juvenile forms of osteoporosis). Osteology, 3(1):184-187, 2000
7) Plotkin H, Glorieux FH. Medical treatment of osteogenesis imperfecta. Drug Development Research 49(3):141-145, 2000
8) Plotkin H, Glorieux FH. [Que hay de nuevo en Osteogenesis Imperfecta?] (What is new in Osteogenesis Imperfecta?) Archivos Argentinos de Pediatria, 99:127-130, 2001.
9) Camargo de Assis M, Plotkin H, Glorieux, FH, Santill C. [Osteogenesis Imperfecta: novos conceitos] (Osteogenesis imperfecta: new concepts). Revista Brasileira de Ortopedia, 37 :323-327, 2002.
10) Plotkin, H. Disorders of Bone Mineralization. eMedicine Journal, 2006 (updated 2008).
11) Plotkin, H, Hypophosphatasia. eMedicine Journal, 2006 (updated 2008)
12) Plotkin, H, Osteogenesis Imperfecta. eMedicine Journal, 2006 (updated 2008)
13) Plotkin, H. Growth and osteogenesis imperfecta. Growth, Genetics and Hormones, (e-journal) vol 23, #2, 2007
14) Plotkin H, Sueiro, R. Osteoporosis in children with neuromuscular diseases and inborn errors of metabolism. Minerva Pediatr, 59:129-35, 2007
15) Esposito P, Plotkin H. Surgical Treatment of Osteogenesis Imperfecta; Current Concepts. Current Concepts in Pediatrics, 20:52-7, 2008
Letters
Plotkin H, A Sawyer, L Bachrach. Mind your “T’s” and “Z’s” Journal of Bone and Joint Surgery Am 85: 1390-1391, 2003
Plotkin H. Bisphosphonates in children with bone diseases. New England Journal of Medicine, 349(21):2068, 2003
Other articles
1) Plotkin H and Glorieux F. Use of bisphosphonates for the treatment of osteogenesis imperfecta. Proceedings of the 7th International Conference on Osteogenesis Imperfecta, Montreal, Canada, :I-17, 1999
2) Plotkin H. Bisphosphonates: questions and answers. Handle With Care, (official bulletin of the Brittle Bone Association of New Zealand), 3:5-7, 2000
3) Plotkin H Osteogenesis Imperfecta issues: constipation. Fact Sheet. Osteogenesis Imperfecta Foundation, USA, 2003
4) Plotkin H Osteogenesis imperfecta: genetics and non-surgical management. Proceedings of the Pediatric Orthopaedic Society of North America One Day Course on Genetics and Orthopaedics :75-82, 2004
5) Plotkin H Osteogenesis imperfecta: mitos y leyendas [Osteogenesis Imperfecta: Myths and Legends]. Voces de Cristal (official bulletin of the Osteogenesis Imperfecta Foundation of Spain), 2004
6) Plotkin H How to get your paper rejected, British Medical Journal, 329 :1469, 2004
7) Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, Wong BL. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004 Neuromuscul Disord. Jan;15(1):80-5, 2005
8) Plotkin H Two questions about osteogenesis imperfecta. Journal of Pediatric Orthopaedics, 26 (1):148-149, 2006
9) Plotkin H Pharmacological treatment of osteogenesis imperfecta. AMOI (OI Foundation of Madrid, Spain,) patients’ guide to OI, 2007.
10) Gordon C, Sanford B, Bianchi ML, Bishop N, Hans D, Kallwarf H, Langman C, Leonard M, Plotkin H, Rauch F, Zemel B. Special Report on the 2007 Pediatric Position Development Conference of the International Society for Clinical Densitometry. Southern Medical Journal, in press, 2008
11) Rauch F, Plotkin H, Dimeglio L, Engelbert RH, Henderson RC, Munns C, Wenkert D, Zeitler P. Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD 2007 Pediatric Official Positions. J Clin Densitom. 2008;11:22-8, 2008
12) Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler D, Hans D, Silverman S, Bishop N, Leonard M, Bianchi M,.Kalkwarf H, Langman C, Plotkin H, Rauch F, Zemel B. Special Report on the 2007 Adult and Pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporosis International, 19(10):1369-78, 2008
13) Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S.International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone, in press, 2008
